
PATENT COOPERATION TREATY

Fro	m the					REC'D 0 1 JU	N 2005
	ERNATIONAL SE	ARCHING AUTH	ORITY			WIPO	PCT
To	D:]	PC	`T	101
						, ,	
see form PCT/ISA/220				WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY			
				Date of mailing			
					(day/month/year) see form PCT/ISA/210 (second sheet)		
Apı	plicant's or agent's file	e reference		<u> </u>			· .
	e form PCT/ISA/2			FOR FURTHER ACTION See paragraph 2 below			
Inte	mational application	No.	International filing date (1		Industry - At I	
PC	PCT/GB2004/005464 23.12.2004			ay/month/year) Priority date (day/month/year) 23.12.2003			
Inte	International Patent Classification (IPC) or both national classification			and IPC			
C0	7D231/12, C07D	413/10, C07D4	01/10, A61K31/415, A	\61P37/02			
	licant			<u> </u>			
ASTEX TECHNOLOGY LIMITED							•
1.	This opinion co	ontains indicatio	ons relating to the foll	owing items:	•		•
	⊠ Box No. I	Basis of the opinion					
	☐ Box No. II	Priority	IIIIOI1				
	☐ Box No. III	•	nent of opinion with reas	ard to novelty. Inventiv	re step and in	duadrial a.a	174
	☐ Box No. IV	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Lack of unity of invention					
	⊠ Box No. V	Reasoned statement under Rule 43bls.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
	☐ Box No. VI	Certain docume	ents cited	sapporting coch state	omont		
	☐ Box No. VII	Certain defects in the international application					
	☐ Box No. VIII	Certain observations on the international application					
2. FURTHER ACTION							
	if a demand for in	temational proli	minons avamination in			•	:
	If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered.						
		date of mailing of	re, considered to be a w together, where approp f Form PCT/ISA/220 or t				ate,
For further options, see Form PCT/ISA/220.							
3. For further details, see notes to Form PCT/ISA/220.							
		, , , = =	O INGPVEZU,				;
Vame	and mailing address	of the ISA		Authority d com			
Name and malling address of the ISA:				Authorized Officer		4	person Personal
	European Pa D-80298 Mu			Lauro, P		.ger	M
		2399 - 0 Tx: 52365	i6 epmu d			ma a	
	Fax: +49 09	2053 - 4400		Telephone No. +49 89	2399-8288	~	m d

Telephone No. +49 89 2399-8288



WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/GB2004/005464

Box No. I Basis of the opinion					
With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.					
This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).					
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:					
a. type of material:					
☐ a sequence listing					
☐ table(s) related to the sequence listing					
b. format of material:					
☐ in written format					
☐ in computer readable form					
c. time of filing/furnishing:					
□ contained in the international application as filed.					
☐ filed together with the international application in computer readable form.					
☐ furnished subsequently to this Authority for the purposes of search.					
In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.					
4 Additional comments:					

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/GB2004/005464

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

57-74

No:

Claims

1-56,75-78

Inventive step (iS)

Yes: Claims

1-78

ij

No: Claims

Yes: Claims

1-68,75-78

No: Claims

69-74

2. Citations and explanations

Industrial applicability (IA)

see separate sheet

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/GB2004/005464

Re Item V.

1. Reference is made to the following document:

D1: WO 01/32653 A (CEPHALON, INC) 10 May 2001 (2001-05-10)

D2: JP 2000 016984 A2 (PFIZER INC., USA) 18 January 2000 (2000-01-18)

2. Novelty

The compound disclosed in preparation 48 on page 173 of the translated Japanese document D2 falls within the definition of formula (I) as claimed in the current application. Novelty is not acknowledged re D2.

3. inventive step

The problem underlying the present application appears to reside in the provision of pyrazole derivatives as protein kinase A and protein kinase B modulators and thus useful in treating abnormal cell growth in a mammal.

Since the structurally closest compounds, which are disclosed in D2 have a different activity, namely delta opioid antagonist activity, and the protein kinase modulators disclosed in D1 are remote in structure compared to the compounds of the present application, inventive step is acknowledged.

4. Further observations:

- Claims 69 to 74 are directed to a method for treatment of the human body by therapy.
- The "linker" group A needs a clearer definition in the claims.
- The possibility of substitutions on the rings (see e.g. E, R1) should be specified in the claims by introducing a list of suitable substituents